STAT2 and type 2 diabetes mellitus: To our knowledge only one other drug apart from canagliflozin, namely the Janus kinase 1 (JAK1)–signal transducer and activator of transcription 2 (STAT2) inhibitor baricitinib, has been shown to decrease TNFR1 levels in individuals with type 2 diabetes [25].